Global Duchenne Muscular Dystrophy Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 1973

Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
In 2018, the global Duchenne Muscular Dystrophy Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Duchenne Muscular Dystrophy Therapeutics development in United States, Europe and China.

The key players covered in this study
Bristol-Myers Squibb
FibroGen (U.S.)
Italfarmaco (Italy)
Marathon
NS Pharma (U.S.)
PTC Therapeutics (U.S.)
Pfizer
ReveraGen BioPharma (U.S.)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (U.S.)

Market segment by Type, the product can be split into
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort

Market segment by Application, split into
Hospitals
Clinics
Home Care Settings

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Duchenne Muscular Dystrophy Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Pain Management Drugs
1.4.3 Corticosteroids
1.4.4 Prednisolone
1.4.5 Prednisone
1.4.6 Deflazacort
1.5 Market by Application
1.5.1 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Home Care Settings
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Duchenne Muscular Dystrophy Therapeutics Market Size
2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Regions
2.2.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (2014-2025)
2.2.2 Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Manufacturers
3.1.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
3.3 Key Players Duchenne Muscular Dystrophy Therapeutics Product/Solution/Service
3.4 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2014-2019)
4.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
5.2 Duchenne Muscular Dystrophy Therapeutics Key Players in United States
5.3 United States Duchenne Muscular Dystrophy Therapeutics Market Size by Type
5.4 United States Duchenne Muscular Dystrophy Therapeutics Market Size by Application

6 Europe
6.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
6.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Europe
6.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type
6.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application

7 China
7.1 China Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
7.2 Duchenne Muscular Dystrophy Therapeutics Key Players in China
7.3 China Duchenne Muscular Dystrophy Therapeutics Market Size by Type
7.4 China Duchenne Muscular Dystrophy Therapeutics Market Size by Application

8 Japan
8.1 Japan Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
8.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Japan
8.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size by Type
8.4 Japan Duchenne Muscular Dystrophy Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
9.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size by Type
9.4 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size by Application

10 India
10.1 India Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
10.2 Duchenne Muscular Dystrophy Therapeutics Key Players in India
10.3 India Duchenne Muscular Dystrophy Therapeutics Market Size by Type
10.4 India Duchenne Muscular Dystrophy Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
11.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Central & South America
11.3 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
11.4 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size by Application

12 International Players Profiles
12.1 Bristol-Myers Squibb
12.1.1 Bristol-Myers Squibb Company Details
12.1.2 Company Description and Business Overview
12.1.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.1.5 Bristol-Myers Squibb Recent Development
12.2 FibroGen (U.S.)
12.2.1 FibroGen (U.S.) Company Details
12.2.2 Company Description and Business Overview
12.2.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.2.4 FibroGen (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.2.5 FibroGen (U.S.) Recent Development
12.3 Italfarmaco (Italy)
12.3.1 Italfarmaco (Italy) Company Details
12.3.2 Company Description and Business Overview
12.3.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.3.5 Italfarmaco (Italy) Recent Development
12.4 Marathon
12.4.1 Marathon Company Details
12.4.2 Company Description and Business Overview
12.4.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.4.5 Marathon Recent Development
12.5 NS Pharma (U.S.)
12.5.1 NS Pharma (U.S.) Company Details
12.5.2 Company Description and Business Overview
12.5.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.5.4 NS Pharma (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.5.5 NS Pharma (U.S.) Recent Development
12.6 PTC Therapeutics (U.S.)
12.6.1 PTC Therapeutics (U.S.) Company Details
12.6.2 Company Description and Business Overview
12.6.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.6.4 PTC Therapeutics (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.6.5 PTC Therapeutics (U.S.) Recent Development
12.7 Pfizer
12.7.1 Pfizer Company Details
12.7.2 Company Description and Business Overview
12.7.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.7.5 Pfizer Recent Development
12.8 ReveraGen BioPharma (U.S.)
12.8.1 ReveraGen BioPharma (U.S.) Company Details
12.8.2 Company Description and Business Overview
12.8.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.8.4 ReveraGen BioPharma (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.8.5 ReveraGen BioPharma (U.S.) Recent Development
12.9 Santhera Pharmaceuticals (Switzerland)
12.9.1 Santhera Pharmaceuticals (Switzerland) Company Details
12.9.2 Company Description and Business Overview
12.9.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.9.5 Santhera Pharmaceuticals (Switzerland) Recent Development
12.10 Sarepta Therapeutics (U.S.)
12.10.1 Sarepta Therapeutics (U.S.) Company Details
12.10.2 Company Description and Business Overview
12.10.3 Duchenne Muscular Dystrophy Therapeutics Introduction
12.10.4 Sarepta Therapeutics (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
12.10.5 Sarepta Therapeutics (U.S.) Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details